Home > Resources > Whitepapers > A New Pharmaceutical Commons: Transforming Drug Discovery

A New Pharmaceutical Commons: Transforming Drug Discovery

November 30, 2017

The Oxford Martin School at the University of Oxford is a worldleading centre of pioneering research that addresses global challenges. We invest in research that cuts across disciplines to tackle a wide range of issues such as climate change, disease and inequality. We support novel, high risk and multidisciplinary projects that may not fit within conventional funding channels. We do this because breaking boundaries can produce results that could dramatically improve the wellbeing of this and future generations. We seek to make an impact by taking new approaches to global problems, through scientific and intellectual discovery, by developing policy recommendations and working with a wide range of stakeholders to translate them into action.

I'm For Real

Enter your details once to access all our information and resources

Spotlight

St John of God Health Care

St John of God Health Care is a leading health care provider, with hospitals, home nursing and social outreach services throughout Australia, New Zealand, and the wider Asia-Pacific region. As a Catholic, not-for-profit group, we return all profits to the communities we serve by: Updating and expanding our facilities and technology Expanding existing services and acquiring new services, and Providing social outreach services to people experiencing disadvantage.

OTHER WHITEPAPERS
news image

COVID-19 Vaccines Production and Analytical Chemistry Solutions

whitePaper | February 2, 2022

Vaccines work by preparing a person’s immune system to recognize and defend itself against a specific disease.

Read More
news image

Best Practices for RIM Business Process Automation

whitePaper | December 15, 2022

Regulatory teams at life science companies are finding that effective regulatory information management (RIM) has become critical to their operations.

Read More
news image

Benefit-Risk Considerations for Product Quality Assessments; Guidance for Industry; DRAFT GUIDANCE

whitePaper | May 10, 2022

This guidance describes the benefit-risk principles applied by FDA when conducting product quality-related assessments of chemistry, manufacturing, and controls (CMC)2 19 information 20 submitted for FDA assessment as part of original new drug applications (NDAs) under section

Read More
news image

Next-Generation Technology, Procedures, and Products Facilitate Biopreservation Best Practices for Cellular Therapies.

whitePaper | August 19, 2022

The quality of procedures and products used for preparing, transporting and storing cells at cryogenic temperatures have a direct impact on post-thaw viability and functionality, as well as the consistency and reliability of biological agents from a Quality perspective.

Read More
news image

Asia Pacific – Clinical trial landscape

whitePaper | November 28, 2022

The Asia-Pacific area is home to around two thirds of the world’s population and has a wide range of cultural, political, economic, and other factors that affect vaccine development, use, and registration.

Read More
news image

Asia Pacific Leads The Way In Cell & Gene Therapy Trials

whitePaper | December 16, 2022

Cell and gene therapies (CGTs) are continuing to gain momentum in life sciences globally. However, Asia Pacific (APAC) has demonstrated the most growth in CGT developers of any other region, with a rise of 10% in H1 2022 compared to 2021.1

Read More

COVID-19 Vaccines Production and Analytical Chemistry Solutions

whitePaper | February 2, 2022

Vaccines work by preparing a person’s immune system to recognize and defend itself against a specific disease.

Read More

Best Practices for RIM Business Process Automation

whitePaper | December 15, 2022

Regulatory teams at life science companies are finding that effective regulatory information management (RIM) has become critical to their operations.

Read More

Benefit-Risk Considerations for Product Quality Assessments; Guidance for Industry; DRAFT GUIDANCE

whitePaper | May 10, 2022

This guidance describes the benefit-risk principles applied by FDA when conducting product quality-related assessments of chemistry, manufacturing, and controls (CMC)2 19 information 20 submitted for FDA assessment as part of original new drug applications (NDAs) under section

Read More

Next-Generation Technology, Procedures, and Products Facilitate Biopreservation Best Practices for Cellular Therapies.

whitePaper | August 19, 2022

The quality of procedures and products used for preparing, transporting and storing cells at cryogenic temperatures have a direct impact on post-thaw viability and functionality, as well as the consistency and reliability of biological agents from a Quality perspective.

Read More

Asia Pacific – Clinical trial landscape

whitePaper | November 28, 2022

The Asia-Pacific area is home to around two thirds of the world’s population and has a wide range of cultural, political, economic, and other factors that affect vaccine development, use, and registration.

Read More

Asia Pacific Leads The Way In Cell & Gene Therapy Trials

whitePaper | December 16, 2022

Cell and gene therapies (CGTs) are continuing to gain momentum in life sciences globally. However, Asia Pacific (APAC) has demonstrated the most growth in CGT
developers of any other region, with a rise of 10% in
H1 2022 compared to 2021.1

Read More
More Whitepapers

Spotlight

St John of God Health Care

St John of God Health Care is a leading health care provider, with hospitals, home nursing and social outreach services throughout Australia, New Zealand, and the wider Asia-Pacific region. As a Catholic, not-for-profit group, we return all profits to the communities we serve by: Updating and expanding our facilities and technology Expanding existing services and acquiring new services, and Providing social outreach services to people experiencing disadvantage.

Events